Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis.

Autor: Costa BA; Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; Department of Medicine, Memorial Sloan Kettering Cancer, New York, New York, USA., Costa TA; Department of Medicine, Federal University of Ceará, Fortaleza, Brazil., Saravia SD; Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Felix N; Department of Medicine, Federal University of Campina Grande, Campina Grande, Brazil., Tan CR; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Korde N; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Richter J; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Jun; Vol. 99 (6), pp. 1056-1065. Date of Electronic Publication: 2024 Mar 15.